NCT06827340

Brief Summary

WB-MRI is a next-generation imaging technique standardized with the first version of MET-RADs-P guidelines.This narrative review aims to analyse the main scientific evidence available in the literature, explaining what WB MRI is and showing its decisive role in metastatic PC.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
104

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 1995

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 1995

Completed
29.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2024

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

January 10, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

February 14, 2025

Completed
Last Updated

February 14, 2025

Status Verified

December 1, 2024

Enrollment Period

29.3 years

First QC Date

January 10, 2025

Last Update Submit

February 13, 2025

Conditions

Prostate Cancer (Adenocarcinoma)

Outcome Measures

Primary Outcomes (6)

  • Identifying the imaging features of metastatic PC in WB-MRI

    from 1995 to april 2024

  • Evaluation of Bone Metastases with WB-MRI

    from 1995 to April 2024

  • Assessment of Nodal Disease

    from 1995 to april 2024

  • Assessment of Visceral Disease

    from 1995 to april 2024

  • Assessing Local Disease and Biochemical Recurrence

    from 1995 to april 2024

  • Response Assessment in Metastatic Prostate Cancer

    from 1995 to april 2024

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Literature with patients with metastatic prostate cancer.

You may qualify if:

  • "Whole Body MRI"
  • "Diffusion Weighted Imaging"
  • "PET-CT and WB-MRI"
  • "Metastatic Prostate Cancer"
  • "Biochemical Recurrence in Metastatic Prostate Cancer"
  • "DWIBS"
  • "Multiparametric MRI"
  • "response assessment in metastatic prostate cancer"
  • "Dixon Method",
  • "bone biopsy in metastatic prostate cancer",
  • "bone metastases in prostate cancer",
  • "MET-RADs".
  • analysis from 1995 to April 2024.

You may not qualify if:

  • duplicates
  • repetitive,
  • irrelevant,
  • unrelated,
  • out-of-date guidelines,
  • case reports

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, Bologna, 40138, Italy

Location

MeSH Terms

Conditions

Prostatic NeoplasmsAdenocarcinoma

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital DiseasesCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic Type

Study Officials

  • Lorenzo Bianchi

    IRCCS Azienda Ospedaliero-Universitaria di Bologna

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 10, 2025

First Posted

February 14, 2025

Study Start

January 1, 1995

Primary Completion

April 1, 2024

Study Completion

April 1, 2024

Last Updated

February 14, 2025

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will not share

Locations

IT(1)